Ruixiang Xia

机构：Anhui Medical University, First Affiliated Hospital of Anhui Medical University · ORCID：0000-0003-2222-3216

发表论文 47 篇 · 总被引 531 次 · h-index 12

代表论文

• A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia (2021 · Journal of Hematology & Oncology · 被引 73)
• Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection (2020 · Leukemia · 被引 49)
• Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor‐naïve patients with myelofibrosis: Results of a phase II trial (2022 · American Journal of Hematology · 被引 33)
• Long non-coding RNA LINC01003 suppresses the development of multiple myeloma by targeting miR-33a-5p/PIM1 axis (2021 · Leukemia Research · 被引 26)
• Case Report: Local Cytokine Release Syndrome in an Acute Lymphoblastic Leukemia Patient After Treatment With Chimeric Antigen Receptor T-Cell Therapy: A Possible Model, Literature Review and Perspective (2021 · Frontiers in Immunology · 被引 23)
• Long non-coding RNA CRNDE suppressing cell proliferation is regulated by DNA methylation in chronic lymphocytic leukemia (2021 · Leukemia Research · 被引 22)